跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
12-k
首页
药物
12-k
12-k
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
PHARMACEUTICAL COMPOSITION COMPRISING K-RAS-SPECIFIC ACTIVATED T CELLS FOR PREVENTION AND TREATMENT OF BREAST CANCER AND METHOD FOR PREPARING SAME
申请人: MYONGJI HOSPITAL
优先权: 2021
WO
2 件公开
PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING MELANOMA COMPRISING K-RAS-SPECIFIC ACTIVATED T CELLS, AND METHOD FOR PREPARING SAME
申请人: MYONGJI HOSPITAL
优先权: 2021
WO
2 件公开
PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING COLORECTAL CANCER COMPRISING K-RAS-SPECIFIC ACTIVATED T CELLS, AND METHOD FOR PREPARING SAME
申请人: MYONGJI HOSPITAL
优先权: 2021
WO
2 件公开
PHARMACEUTICAL COMPOSITION COMPRISING ACTIVATION T CELLS SPECIFIC TO K-RAS FOR PREVENTING AND TREATING LUNG ADENOCARCINOMA AND PREPARATION METHOD THEREFOR
申请人: MYONGJI HOSPITAL
优先权: 2021
WO
2 件公开
PHARMACEUTICAL COMPOSITION COMPRISING ACTIVATED T CELLS SPECIFIC TO K-RAS FOR PREVENTING AND TREATING LUNG PAPILLARY ADENOCARCINOMA AND METHOD FOR PREPARING SAME
申请人: MYONGJI HOSPITAL
优先权: 2021
WO
2 件公开
Double-functional staphylokinase mutant having platelet aggregation resistance and fibrinolytic activity, application and preparation method thereof
申请人: HEBEI NORMAL UNIVERSITY
优先权: 2007
CN
种检测人基质金属蛋白酶‑12活性的荧光多肽底物
申请人: 昆明医科大学第附属医院
优先权: 2014
CN
Intrauterine contraceptive device
申请人: KARPATI MELINDA-KINGA
优先权: 2006
CN
EP
US
4 件公开
药物
反馈